Abstract

HLA-E is a non-classical class I MHC protein involved in innate and adaptive immune recognition. While recent studies have shown HLA-E can present diverse peptides to NK cells and T cells, the HLA-E repertoire recognized by CD94/NKG2x has remained poorly defined, with only a limited number of peptide ligands identified. Here we screen a yeast-displayed peptide library in the context of HLA-E to identify 500 high-confidence unique peptides that bind both HLA-E and CD94/NKG2A or CD94/NKG2C. Utilizing the sequences identified via yeast display selections, we train prediction algorithms and identify human and cytomegalovirus (CMV) proteome-derived, HLA-E-presented peptides capable of binding and signaling through both CD94/NKG2A and CD94/NKG2C. In addition, we identify peptides which selectively activate NKG2C+ NK cells. Taken together, characterization of the HLA-E-binding peptide repertoire and identification of NK activity-modulating peptides present opportunities for studies of NK cell regulation in health and disease, in addition to vaccine and therapeutic design.

HLA-E is a highly conserved MHC-l recognized by NK and T cells. The authors characterize HLA-E-presented peptides recognized by CD94/NKG2x, identifying human and CMV-derived peptide ligands which can modulate NK cell activity when presented by HLA-E, including for selective NK cell activation.

Details

Title
High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation
Author
Huisman, Brooke D. 1 ; Guan, Ning 1   VIAFID ORCID Logo  ; Rückert, Timo 2   VIAFID ORCID Logo  ; Garner, Lee 3 ; Singh, Nishant K. 4 ; McMichael, Andrew J. 3   VIAFID ORCID Logo  ; Gillespie, Geraldine M. 3   VIAFID ORCID Logo  ; Romagnani, Chiara 5   VIAFID ORCID Logo  ; Birnbaum, Michael E. 6   VIAFID ORCID Logo 

 Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.516087.d); Department of Biological Engineering, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Innate Immunity, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Leibniz Institut, Berlin, Germany (GRID:grid.418217.9) (ISNI:0000 0000 9323 8675) 
 University of Oxford, Centre for Immuno-Oncology, Old Road Campus Research Building, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.516087.d); Ragon Institute of MGH, MIT, and Harvard, Cambridge, USA (GRID:grid.461656.6) (ISNI:0000 0004 0489 3491) 
 Innate Immunity, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Leibniz Institut, Berlin, Germany (GRID:grid.418217.9) (ISNI:0000 0000 9323 8675); Charité - Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.516087.d); Department of Biological Engineering, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Ragon Institute of MGH, MIT, and Harvard, Cambridge, USA (GRID:grid.461656.6) (ISNI:0000 0004 0489 3491) 
Pages
4809
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2848020778
Copyright
© The Author(s) 2023. corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.